1. Do Y, Kwak J, Kim J, Oh S, Kim SH, Moon YC, Lee S, Choi CW, Zang DY, Kim DW, Park J, Kim H Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) Br J Haematol. 2020 Apr; 189(2): 303–312
2. Kang J, Chang Y, Ahn J, Oh S, Koo DH, Lee YG, Shin H, Ryu S. Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population Int J Cancer. 2019 Dec 15;145(12):3267-3275.
3. Lee YG, Chang Y, Kang J, Koo DH, Lee SS, Ryu S, Oh S. Risk factors for incident anemia of chronic diseases: A cohort study. PLoS One. 2019 May 6;14(5)
4. Koo DH, Do IG, Oh S, Lee YG, Kim K, Sohn JH, Park SK, Yang HJ, Jung YS, Park DI, Jeong KU, Kim HO, Kim H, Serrero G, Chun HK; KBSMC Colorectal Cancer Team. Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. Pathol Oncol Res. 2018 Oct 30.
5. Lee YG, Jung I, Koo DH, Kang DY, Oh TY, Oh S, Lee SS.
Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer. 2019 May;27(5):1945-1949.
6. Yang J, Min KW, Kim DH, Son BK, Moon KM, Wi YC, Bang SS, Oh YH, Do SI, Chae SW, Oh S, Kim YH, Kwon MJ. High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts. PLoS One. 2018 Aug 24
7. Kim H, Kim S, Kim HJ, Kim YK, Kwak JY, Yhim HY, Kim SH, Do YR, Oh S, Lee SE, Jootar S, Cui JW, Kim DW. Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2018 Oct;18
8. Lee SE, Choi SY, Kim SH, Jootar S, Kim HJ, Sohn SK, Park JS, Kim SH, Zang DY, Oh SJ, Kim DW. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. Leuk Res. 2018
8. Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, Lee JI. Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Med. 2018 May;7(5):1766-1773.
9. Min KW, Kim DH, Son BK, Kim EK, Ahn SB, Kim SH, Jo YJ, Park YS, Seo J, Oh YH, Oh S, Kim HY, Kwon MJ, Min SK, Park HR, Choe JY, Jeon JY, Ha HI, Lee JW. Invasion Depth Measured in Millimeters is a Predictor of Survival in Patients with Distal Bile Duct Cancer: Decision Tree Approach. World journal of surgery. 2017;41(1):232-40.